-- Alterity Therapeutics（ASX：ATH）週一向澳洲證券交易所提交的文件顯示，該公司在與美國食品藥品監督管理局（FDA）舉行的第二次C類會議上獲得了積極的反饋，該會議旨在討論其用於治療多系統萎縮症（MSA）的候選藥物ATH434的三期臨床試驗計劃。 MSA是一種進行性神經退化性疾病，會影響自主神經和運動功能，目前尚無核准的疾病修飾療法。 該文件還補充道，美國FDA就該計畫的化學、生產和控制方面提供了支持性的書面回饋，補充了先前在另一次C類會議上就臨床藥理學和非臨床開發方面提供的指導意見。
Related Articles
Asia
Sunshine Metals Completes Resource Definition Drilling at Queensland Gold-Dominant Deposit
Sunshine Metals (ASX:SHN) completed resource definition drilling at the Liontown gold panel, a gold-dominant deposit which is part of its Ravenswood consolidated project in Queensland, in late March, according to a Monday Australian bourse filing.The mining study and mineral resource for the Liontown project will be further updated and upgraded in May to incorporate results from the grade control drilling program.
$ASX:SHN
Asia
Wanxiang Qianchao Q1 Profit Down 16%; Shares Slide 3%
Wanxiang Qianchao (SHE:000559) posted first-quarter attributable net profit of 246.8 million yuan, down 16% from 293.3 million yuan the previous year.Earnings per share declined to 0.074 yuan from 0.089 yuan, according to a weekend filing with the Shenzhen bourse.Operating revenue slipped 20% year over year to 2.80 billion yuan from 3.50 billion yuan.Shares of the auto parts manufacturer declined 3% in recent trade.
$SHE:000559
Asia
Eng Kah Seeks 10% Share Buyback Mandate; Shares Rise 3%
Eng Kah (KLSE:ENGKAH) is seeking its shareholders' approval to renew share buyback authority to purchase up to 10% of the issued shares in the company's upcoming annual general meeting, according to a Friday Malaysian bourse filing.Shares gained about 3% in Monday's afternoon trade.The manufacturer of cosmetics, personal care, household, and perfume products will share a detailed statement of the repurchase plan with shareholders in due time.
$KLSE:ENGKAH